| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | HCAT | Common Stock | Options Exercise | $561K | +35.4K | +12.52% | $15.84 | 319K | 07 Jun 2021 | Direct | |
| transaction | HCAT | Common Stock | Sale | -$597K | -11.1K | -3.49% | $53.72* | 308K | 07 Jun 2021 | Direct | F1, F2 |
| transaction | HCAT | Common Stock | Sale | -$163K | -2.99K | -0.97% | $54.54* | 305K | 07 Jun 2021 | Direct | F1, F3 |
| transaction | HCAT | Common Stock | Sale | -$2.15M | -38.5K | -12.63% | $55.80* | 266K | 07 Jun 2021 | Direct | F1, F4 |
| transaction | HCAT | Common Stock | Sale | -$586K | -10.4K | -3.92% | $56.23* | 256K | 07 Jun 2021 | Direct | F1, F5 |
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | HCAT | Stock Option (Right to Buy) | Options Exercise | $0 | -35.4K | -21.48% | $0.00 | 130K | 07 Jun 2021 | Common Stock | 35.4K | $15.84 | Direct | F6 |
| Id | Content |
|---|---|
| F1 | The sales reported on this Form 4 was made pursuant to a written trading plan adopted by the Reporting Person on March 4, 2021, in accordance with Rule 10b5-1. |
| F2 | Represents the weighted average sale price of the shares sold ranging from $53.08 to $54.07 per share, inclusive. |
| F3 | Represents the weighted average sale price of the shares sold ranging from $54.10 to $55.04 per share, inclusive. |
| F4 | Represents the weighted average sale price of the shares sold ranging from $55.14 to $56.13 per share, inclusive. |
| F5 | Represents the weighted average sale price of the shares sold ranging from $56.14 to $56.37 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in Footnotes (2) though (5). |
| F6 | 25% of the 299,748 shares underlying the option vested in an annual installment on February 5, 2020 and the remaining balance vested or will vest in equal monthly installments until the option vests in full on February 5, 2023. |